Welcome to our dedicated page for Utah Med Prods SEC filings (Ticker: UTMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Utah Medical Products Inc. filings document formal disclosures for a Utah-incorporated medical device manufacturer whose common stock trades on Nasdaq under the symbol UTMD. Recent Form 8-K reports furnish quarterly and annual financial information, including sales, margins, earnings measures and exhibits containing the company's financial-performance releases.
The filing record also covers governance and capital-return matters. Definitive proxy materials describe director elections, auditor ratification, advisory executive-compensation votes and annual meeting procedures, while 8-K reports record stockholder voting results, board appointments, committee service, director compensation arrangements and quarterly dividend announcements.
Utah Medical Products Inc. (UTMD) reported an equity compensation award to its Principal Financial Officer. On 10/31/2025, the officer received an employee stock option to buy 500 shares of UTMD common stock at an exercise price of $58.1 per share. The option expires on 10/31/2035 and will vest 25% on 1/1/27, with an additional 6.25% vesting on 4/1/27 and on the first day of each calendar quarter thereafter, becoming fully exercisable on 1/1/30. Following this grant, the officer beneficially owned 5,600 derivative securities directly.
Utah Medical Products (UTMD) filed its Q3 2025 report showing sales of $9.812M and diluted EPS of $0.82. Gross margin was 57.1% and operating margin 26.6%, both lower year over year as operating income fell 21.9%.
Management cited two outside‑U.S. distributor cancellations/delays that reduced shipments by $976 and revenues by $581, and recorded a $395 bad‑debt reserve tied to a China distributor fee. Non‑operating income eased with lower cash yields. By category, Q3 sales were Gynecology/Electrosurgery/Urology $4.954M (down), Neonatal $2.176M (up), Blood Pressure Monitoring $1.643M (down), and Labor & Delivery $1.039M (flat).
Year to date, sales were $29.475M and EPS $2.68. Cash and investments were $84.267M, current liabilities $3.011M. The company repurchased 130,984 shares for $7.361M and paid $3.006M in dividends. Management now expects 2025 revenue to be 6–7% lower than 2024 and EPS of $3.40–$3.50.
Utah Medical Products (UTMD) expanded its Board from five to six members and appointed Kevin Timken as a director. He will serve on the Audit Committee and the Compensation and Benefits Committee. Timken previously advised UTMD on U.S. SEC matters during a 25-year legal career.
As a director, Timken received 10,000 stock options with an exercise price of $58.10 per share, vesting over four years, and the standard Board fee of $7,650 per quarter, pro‑rated for the final quarter of 2025.
UTMD also increased its regular quarterly cash dividend to $0.31 per share, payable on January 5, 2026 to shareholders of record at the close of business on December 16, 2025.
Utah Medical Products, Inc. furnished an update on its results under Item 2.02. The company attached a press release (Exhibit 99.1) with financial information for the three and nine months ended September 30, 2025, along with forward-looking statements for 2025 and beyond.
The information was furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into Securities Act or Exchange Act filings.
Brandes Investment Partners, L.P. filed an amendment to Schedule 13G reporting beneficial ownership of 333,204 common shares of Utah Medical Products Inc (UTMD), representing 10.39% of the class. The filing shows Brandes has shared voting power over 286,784 shares and shared dispositive power over 333,204 shares, with no sole voting or dispositive power. The form states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing identifies the reporting person as an investment adviser organized in Delaware and lists principal office at 4275 Executive Square, La Jolla, CA. The signature on the amendment is dated 09/02/2025.
Brandes Investment Partners, L.P. filed an amendment to Schedule 13G reporting beneficial ownership of 333,204 common shares of Utah Medical Products Inc (UTMD), representing 10.39% of the class. The filing shows Brandes has shared voting power over 286,784 shares and shared dispositive power over 333,204 shares, with no sole voting or dispositive power. The form states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing identifies the reporting person as an investment adviser organized in Delaware and lists principal office at 4275 Executive Square, La Jolla, CA. The signature on the amendment is dated 09/02/2025.
Brandes Investment Partners, L.P. filed an amendment to Schedule 13G reporting beneficial ownership of 333,204 common shares of Utah Medical Products Inc (UTMD), representing 10.39% of the class. The filing shows Brandes has shared voting power over 286,784 shares and shared dispositive power over 333,204 shares, with no sole voting or dispositive power. The form states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing identifies the reporting person as an investment adviser organized in Delaware and lists principal office at 4275 Executive Square, La Jolla, CA. The signature on the amendment is dated 09/02/2025.
Brian L. Koopman, Principal Financial Officer of Utah Medical Products Inc. (UTMD), reported the sale of 50 shares of the company's common stock on 09/04/2025 at a price of $62.75 per share. Following the reported transaction, Mr. Koopman beneficially owns 832 shares in a direct capacity. The Form 4 is signed by Mr. Koopman on 09/05/2025.
Paul O. Richins, a director of Utah Medical Products, sold 100 shares of the company's common stock on 08/25/2025 at $60.34 per share. After the sale he beneficially owns 21,136 shares indirectly, held across a family trust, a personal IRA, his spouse's IRA and his sons' accounts: 18,948 shares in the Richins Family Trust, 1,245 in his spouse's IRA, 443 by his sons and 500 in his own IRA. The Form 4 indicates the filing was made by one reporting person and is signed by Mr. Richins.
Brandes Investment Partners, L.P. reports beneficial ownership of 271,537 common shares of Utah Medical Products, representing 7.39% of the class as stated in Item 4. The filing shows Brandes holds shared voting and shared dispositive power over these shares and reports no sole voting or dispositive power, indicating it does not exercise unilateral control.
The statement is filed on Schedule 13G/A and classifies the reporting person as IA, PN (investment adviser/portfolio manager). The filer certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Utah Medical Products (UTMD) reported Q2 2025 net sales of $9,953 thousand, down 4.3% from $10,400 in Q2 2024, and first-half sales of $19,663 thousand, down 9.6% year-over-year. Gross profit fell to $5,595 thousand (56.2% margin) from $6,253 thousand (60.1%), driven by lower volumes, an unfavorable product mix in Ireland and reduced orders from former large OEM customer PendoTECH. Net income was $3,048 thousand in Q2 and $6,089 thousand for 1H 2025; diluted EPS were $0.94 and $1.86, respectively.
The company remains well capitalized with $82.2 million in cash and investments, no debt, ongoing dividends and opportunistic share repurchases (119,255 shares repurchased in 1H 2025 for $6.7 million). Management expects full-year PendoTECH sales to be about $2.0 million lower than 2024, is tracking adjusted EBITDA near targets, and highlights potential OUS tariff and distributor-timing risks that could affect 2H results.